Dolutegravir + Lamivudine is a fixed‑dose combination widely used in the management of HIV infection, offering a streamlined approach to antiretroviral therapy. Dolutegravir belongs to the class of integrase strand transfer inhibitors, which act by blocking the integration of viral DNA into the host genome, a critical step in the replication cycle of HIV. Lamivudine, on the other hand, is a nucleoside reverse transcriptase inhibitor that interferes with the viral reverse transcriptase enzyme, preventing the conversion of viral RNA into DNA. Together, these two agents provide a potent dual mechanism of action that suppresses viral replication effectively. The combination is valued for its simplicity, as it reduces pill burden and enhances adherence, which is crucial for long‑term viral suppression and prevention of resistance. Clinicians often consider this regimen as part of first‑line therapy because of its efficacy, tolerability, and convenience. It is also used in treatment‑naïve patients as well as those switching from more complex regimens, offering a balance of potency and ease of use. Beyond its therapeutic role, the combination contributes to public health goals by lowering transmission risk through sustained viral suppression. Its co‑formulation into a single tablet underscores the modern emphasis on patient‑friendly regimens that support adherence and improve quality of life. Overall, Dolutegravir + Lamivudine represents a cornerstone in contemporary HIV management, combining robust antiviral activity with practical advantages that align with both individual patient needs and broader healthcare strategies.